Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.63 |
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.57 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.57 |
| ▸ | CTSB | P07858 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29350618 | 1.00 | SLC6A2 (0.63) | SLC6A2DPP3OPRM1OPRD1CAPN1 | |
| SCHEMBL30392261 | 0.90 | DPP3 (0.61) | SLC6A2DPP3OPRM1CAPN1CTSB | |
| SCHEMBL29772686 | 0.90 | DPP3 (0.65) | SLC6A2DPP3OPRM1 | |
| SCHEMBL29577213 | 0.90 | DPP3 (0.65) | SLC6A2DPP3OPRM1 | |
| SCHEMBL30659496 | 0.90 | DPP3 (0.64) | DPP3OPRM1OPRD1 | |
| SCHEMBL29683171 | 0.90 | KISS1R (0.62) | SLC6A2OPRM1CAPN1CTSB | |
| Spinorphin SCHEMBL25273730 | 0.89 | KISS1R (0.60) | SLC6A2DPP3OPRM1CAPN1CTSB | |
| Spinorphin SCHEMBL25217672 | 0.89 | KISS1R (0.60) | SLC6A2DPP3OPRM1CAPN1CTSB | |
| SCHEMBL29363938 | 0.88 | SLC6A2 (0.78) | SLC6A2OPRM1OPRD1 | |
| Endomorphin-1 SCHEMBL21811384 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3921420-B1 | DRUG DELIVERY COMPOSITIONS FOR OCULAR ADMINISTRATION OF THERAPEUTICS AND METHODS OF USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260053737-A1 | METHODS AND COMPOSITIONS FOR SUSTAINED RELEASE MICROPARTICLES FOR OCULAR DRUG DELIVERY | OHIO STATE INNOVATION FOUNDATION (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260007778-A1 | METHODS FOR TREATING AND DIAGNOSING BLINDING EYE DISEASES | TRANSLATUM MEDICUS INC (CA) | 2026-01-08 | — | — | US | disclosed |
| US-20250387449-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | ALBIREO AB (SE) | 2025-12-25 | — | — | US | disclosed |
| EP-4662203-A1 | BINDARIT CONJUGATES, COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES OR DISORDERS | Translatum Medicus Inc. (CA) | 2025-12-17 | — | — | EP | disclosed |
| EP-3956813-B1 | DETECTION, PREDICTION, AND CLASSIFICATION FOR OCULAR DISEASE | TRACERY OPHTHALMICS INC (CA) | 2025-11-26 | — | — | EP | disclosed |
| US-12377171-B2 | Methods for treating and diagnosing blinding eye diseases | Translatum Medicus Inc. (CA) | 2025-08-05 | — | — | US | disclosed |
| US-12357564-B2 | Methods and compositions for sustained release microparticles for ocular drug delivery | OHIO STATE INNOVATION FOUNDATION (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250152781-A1 | TISSUE ENGINEERING AND DRUG DELIVERY DEVICE | OHIO STATE INNOVATION FOUNDATION | 2025-05-15 | — | — | US | disclosed |
| US-20240404619-A1 | Machine Learning and Molecular Simulation Based Methods for Enhancing Binding and Activity Prediction | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2023133560-A2 | TISSUE ENGINEERING AND DRUG DELIVERY DEVICE | OHIO STATE INNOVATION FOUNDATION (US) | 2023-07-13 | — | — | WO | disclosed |
| US-11660266-B2 | Methods and compositions for sustained release microparticles for ocular drug delivery | OHIO STATE INNOVATION FOUNDATION (US) | 2023-05-30 | — | — | US | disclosed |
| WO-2022271255-A1 | TISSUE-ENGINEERED SCAFFOLDS AND METHODS OF MAKING | GEORGIA TECH RESEARCH CORPORATION (US) | 2022-12-29 | — | — | WO | disclosed |
| US-11529340-B2 | Combination for treating pain | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220226446-A1 | NEUROTOXIN COMPOSITIONS FOR USE IN IMPROVING LUNG FUNCTION | BONTI INC (US) | 2022-07-21 | — | — | US | disclosed |
| US-11383084-B2 | Treatment of dermatological conditions via neuromodulation | PALO ALTO INVESTORS (US) | 2022-07-12 | — | — | US | disclosed |
| US-20220207729-A1 | DETECTION, PREDICTION, AND CLASSIFICATION FOR OCULAR DISEASE | TRACERY OPHTHALMICS INC. (CA) | 2022-06-30 | — | — | US | disclosed |
| US-20220117888-A1 | DRUG DELIVERY COMPOSITIONS FOR OCULAR ADMINISTRATION OF THERAPEUTICS AND METHODS OF USE THEREOF | OHIO STATE INNOVATION FOUNDATION | 2022-04-21 | — | — | US | disclosed |
| US-20220118159-A1 | ANTIOXIDANT-RELEASING VITREOUS SUBSTITUTES AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION | 2022-04-21 | — | — | US | disclosed |
| EP-3956813-A1 | DETECTION, PREDICTION, AND CLASSIFICATION FOR OCULAR DISEASE | Boyd, Shelley (CA) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053737-A1 | METHODS AND COMPOSITIONS FOR SUSTAINED RELEASE MICROPARTICLES FOR OCULAR DRUG DELIVERY | ARG1, ARG2, PDE6D | SLC6A2 1265/4885DPP3 1259/4885OPRM1 681/4885 |
| US-11660266-B2 | Methods and compositions for sustained release microparticles for ocular drug delivery | PDE6C, CHMP4B, PDE6D | SLC6A2 221/4885DPP3 1091/4885OPRM1 1800/4885 |
| US-20260007778-A1 | METHODS FOR TREATING AND DIAGNOSING BLINDING EYE DISEASES | AGER, ALDH1A2, RBP1 | SLC6A2 174/4885DPP3 1130/4885OPRM1 1700/4885 |
| US-12357564-B2 | Methods and compositions for sustained release microparticles for ocular drug delivery | PDE6C, CHMP4B, PDE6D | SLC6A2 221/4885DPP3 1091/4885OPRM1 1800/4885 |
| US-20250387449-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | SLC10A2, SLC10A1, ABCB11 | SLC6A2 60/4885DPP3 896/4885OPRM1 1363/4885 |
| US-12377171-B2 | Methods for treating and diagnosing blinding eye diseases | ALDH1A2, RBP1, RBP4 | SLC6A2 2985/4885DPP3 584/4885OPRM1 4602/4885 |
| US-11529340-B2 | Combination for treating pain | OPRL1, ACHE, OPRK1 | SLC6A2 644/4885DPP3 1145/4885OPRM1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.